Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

The stock's fall snapped a four-day winning streak.

Shares of Eli Lilly & Co. LLY advanced 1.61% to $725.22 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 2.05% to 5,921 ...

Briefly, S&P 500 constituents Moderna (MRNA 25.15, +1.50, +6.34%), Fiserv (FI 166.07, +6.94, +4.36%), and EliLilly (LLY 757.74, +25.95, +3.55%) pepper the top of the standings. Shares of MRNA were ...

Wall Street stocks ended mixed on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in U.S. trade negotiations with Japan against concerns about the interest rate outlook.

Eli Lilly (LLY) closed at $786.92 in the latest trading session, marking a +1.19% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.61% for the day.

Eli Lilly down 19% in May, worst month since 2009. Underperformed S&P 500 by 24%, worst since August 2000. June shows promise, historically Lilly’s strongest month. Get daily-updated rankings ...

Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...

Seasonal trends highlight 10 S&P 500 stocks with strong June performance. Tesla leads the list, joined by consistent gainers like Eli Lilly.

Shares of Eli Lilly (LLY) jumped 16% Thursday morning to lead S&P 500 gainers after the pharmaceutical company released clinical trial results for its oral weight-loss drug that "demonstrated ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See why LLY is a hold.